Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Here's Why

Key Points

• Shares gapped up to open at $73.88 from a $71.46 close, though the stock was last around $71.63 and trading down about 1.3% on light volume.
• Analysts are broadly positive — five Buy ratings and one Hold produce a consensus "Moderate Buy" and an average price target of $124.50, with individual targets up to $147.
• Bright Minds is a clinical‑stage biotech developing psychedelic‑inspired small‑molecule therapies (lead candidate BMB‑101) and recently reported quarterly EPS of -$0.70, beating estimates; market cap is about $720 million.

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $71.46, but opened at $73.88. Bright Minds Biosciences shares last traded at $71.6330, with a volume of 2,903 shares.

Analysts Set New Price Targets

DRUG has been the subject of several analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $80.00 price objective on shares of Bright Minds Biosciences in a research report on Friday, January 2nd. Wall Street Zen raised Bright Minds Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, March 21st. Robert W. Baird set a $126.00 price objective on Bright Minds Biosciences in a research report on Friday, February 13th. BTIG Research reaffirmed a "buy" rating and set a $147.00 price objective on shares of Bright Minds Biosciences in a research report on Monday, March 30th. Finally, HC Wainwright upped their price objective on Bright Minds Biosciences from $115.00 to $145.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $124.50.

Bright Minds Biosciences Trading Down 1.3%

The firm has a market capitalization of $720.36 million, a PE ratio of -38.45 and a beta of -5.34. The business has a 50 day moving average price of $77.39 and a 200-day moving average price of $72.56.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.98) by $0.28. On average, equities research analysts forecast that Bright Minds Biosciences Inc. will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Bright Minds Biosciences

Large investors have recently bought and sold shares of the stock. Braidwell LP acquired a new position in Bright Minds Biosciences in the third quarter valued at approximately $18,422,000. Gordian Capital Singapore Pte Ltd acquired a new position in Bright Minds Biosciences in the third quarter valued at approximately $73,000. Virtu Financial LLC acquired a new position in Bright Minds Biosciences in the fourth quarter valued at approximately $226,000. Price T Rowe Associates Inc. MD bought a new position in Bright Minds Biosciences in the 4th quarter worth approximately $221,000. Finally, New York State Common Retirement Fund bought a new position in Bright Minds Biosciences in the 2nd quarter worth approximately $107,000. Institutional investors and hedge funds own 40.52% of the company's stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.